Date
11 December 2024Location
Online via Webex at 13:00-14:00About the event
Speakers from NHS England and NHS SPS provided an overview of their role in introducing biosimilar and key generic medicines and how this supports the integrated care system. Information about biosimilar and key generic medicines expected in 2025/26 was provided with an opportunity to ask questions and share experience.
This webinar was intended for commissioners and healthcare professionals providing NHS-commissioned care in England. It was not recorded as some information is commercially confidential and subject to change.
Why it’s important
Implementation of biosimilar and key generic medicines requires collaborative working across the system. Use of biological medicines, including biosimilars, in clinical practice is well established and rapidly increasing. Timely implementation and use of biosimilar and key generic medicines offers the NHS opportunities to deliver better value for certain conditions.
What will be covered
- An overview of NHS England’s role in planning and implementing biosimilar and key generic medicines.
- An understanding of NHS SPS role and scope in supporting the system to implement biosimilar and key generic medicines.
- Information to support planning and implementation for biosimilar and key generic medicines in 2025/26.
Speakers
A range of speakers from SPS and other organisations will run this event.
Non-SPS speakers
Fiona Bride
Director of Medicines Value & Access, NHS England
SPS speakers
Learn more about the SPS team who facilitated this event.
Resources
The event was not recorded as some information is commercially confidential and subject to change.
Contact us
Please contact the Admin Team if you have any questions.